Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%.

Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%. - Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001964

Enrollment

Registered

2009-05-14

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

TAPROS ophthalmic solution 0.0015%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients, over 18mmHg in intra ocular pressure, at least 4weeks Xalatan TM ophthalmic solution treatment and at least 4weeks Travatan z TM ophthalmic solution treatment. 2)Patients, without 20% ocular hypotensive effects, at least 4weeks Xalatan TM ophthalmic solution treatment and at lease 4weeks Travatan z TM ophthalmic solution treatment. 3)Patients, be graded under stage4 at Kozaki's classification.

Exclusion criteria

Exclusion criteria: 1)Presence of any external disease and inflammation of the eye. 2)History of intraocular surgery within one month. 3)Patients with Drug-induced hypersensitivity syndrome. 4)Patients with maintain over 35mmHg in intraocular pressure over one week. 5) The investigator declares any subject ineligible for any sound medical reason.

Design outcomes

Primary

Measure	Time frame
Intraocular pressure reduction, % reduction of intraocular pressure.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026